ANCA-assoziierte Vaskulitis

• Literatur

• 1 Haubitz M. Vaskulitiden. Der Nephrologe 2016; 11: 124-133
• 2 Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in ANCA-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 1166-1173
• 3 Jayne D, Rasmussen N, Andrassy K et al. European Vasculitis Study Group. A randomized trial of maintenance herapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
• 4 Harper L, Morgan MD Walsh et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-960
• 5 Karras A, Segelmark M, Jayne D. Randomized controlled trial of treatment withdrawal in the remission phase of ANCA vasculitis: The REMAIn Study. J Am Soc Nephrol 2015; 26: 7A Abstract
• 6 Pagnoux C, Mahr A, Hamidou MA et al. French Vasculitis Study Group. Azathioprine or methotrexat maintance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-2803
• 7 Puéchal X, Pagnoux C, Perrodeau É et al. French Vasculitis Study Group. Long-term outcomes among participants in the WEGENt trial of remission-maintenance therapy for granulomatosis with polyangiitis or microscopic polyangiitis. Arthritis Rheumatol 2016; 68: 690-701
• 8 Metzler C, Miehle N, Manger K et al. German Network of Rheumatic Diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener‘s granulomatosis. Rheumatology (Oxford) 2007; 46: 1087-1091
• 9 Hiemstra TF, Walsh M, Mahr A et al. European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in ANCA-associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 2381-2388
• 10 Guillevin L, Pagnoux C, Karras A et al. French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1171-1180
• 11 Jones RB, Tervaert JW, Hauser T et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. New Engl J Med 2010; 363: 211-220
• 12 Stone JH, Merkel PA, Spiera R et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232